Overall healthy adults with the Moderna COVID vaccine had 93% vaccine effectiveness against hospitalization over five months compared to those with 88% protection with Pfizer and 71% from the Johnson & Johnson vaccine, a new report out Friday from the CDC shows.
Why it matters: The report comes as the Food and Drug Administrations meets Friday to consider whether to endorse a contentious plan for booster shots among the fully vaccinated.
Get market news worthy of your time with Axios Markets. Subscribe for free.
The higher effectiveness of Moderna could be due to the higher mRNA content or the difference between the timing between doses, the authors note.
Still, all three vaccines provided “substantial protection," the CDC says, despite both mRNA vaccines providing "more protection” than the J&J shot.
The big picture: The real-world data coincides with previous findings of how Moderna may maintain higher effectiveness over time than the other shots available in the United States.
The waning effectiveness in Pfizer may raise future questions about whether the two mRNA vaccines should be treated the same way policy-wise, Axios' Caitlin Owens reports.
By the numbers: The sample size was from nearly 3,700 people at 21 hospitals in 18 states from March 11 to Aug. 15. Patients with immunocompromising conditions were excluded from the report.
About 13% were fully vaccinated with Moderna, 20% were fully vaccinated with Pfizer and 3.1% had J&J.
Vaccine effectiveness for those 14-120 days after the second dose of Moderna was 93% and dropped to 92% after about four months, the data show.
What they're saying: "Understanding differences in [vaccine effectiveness] by vaccine product can guide individual choices and policy recommendations regarding vaccine boosters," the study's authors wrote.
"All FDA-approved or authorized COVID-19 vaccines provide substantial protection against COVID-19 hospitalization," they added.
Like this article? Get more from Axios and subscribe to Axios Markets for free.